Alcon will be a spin off NVS but they will keep some of the reg profits/revenues of course, let Alcon go and not worry about finding a whole buyout. Nobody wants “Alcon” totally in a purchase deal, way too expensive, NVS will let Alcon somewhat go but reep some of those profits in doing so for the time being, maybe we can eliminate some of the NVS bs and let the company flow again on its own and NVS can suck some blood for the time being.
Alcon FTW is still profitable just not enough growth exponentially for Novartis demands currently. But for the next few years Alcon FTW will do fine in profits, regardless of the percentage of ownership or control. Where they went wrong was outsourcing so many support groups and making life much more difficult for the mfg process
